Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05434650
Other study ID # ABT-CIP-10436
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 21, 2022
Est. completion date November 30, 2026

Study information

Verified date May 2024
Source Abbott Medical Devices
Contact Todd Stirman
Phone 972-526-9625
Email todd.stirman@abbott.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This post-approval study is designed to provide continued real-world clinical evidence to confirm the safety and long-term effectiveness of atrial fibrillation (AF) radiofrequency (RF) technologies (e.g. TactiCathâ„¢ Contact Force Ablation Catheter, Sensor Enabledâ„¢ (TactiCath SE)) for the treatment of AF.


Description:

This post-approval study is a prospective, non-randomized, single arm, multicenter, observational study to evaluate the continued safety and effectiveness of AF RF technologies, including the TactiCath SE. The primary effectiveness endpoint will be the proportion of subjects with freedom from AF recurrence after the initial catheter ablation procedure through 12 months of follow-up (includes a 90-day blanking period). Secondary effectiveness endpoints will be the proportion of subjects with freedom from AF recurrence after the initial catheter ablation procedure through 24 and 36 months of follow-up (includes a 90-day blanking period). The acute primary safety endpoint will be the rate of device and/or procedure-related serious adverse events (SAE) with onset within 7-days of the index ablation procedure utilizing the study catheter. The secondary, long-term safety endpoint will be the rate of device and/or procedure-related SAEs from the index ablation procedure. An independent Clinical Event Committee (CEC) will review all Adverse Device Effects (ADEs) and SAEs and will adjudicate causality relative to the primary safety endpoints.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date November 30, 2026
Est. primary completion date October 31, 2024
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Subject must provide written informed consent prior to any clinical investigation-related procedure. 2. Documented symptomatic persistent AF, which is defined as continuous AF sustained beyond 7 days and less than 1 year that is documented by a physician's note AND one of the following: 1. a 24-hour Holter within 180 days prior to consent/enrollment, showing continuous AF OR 2. two electrocardiograms (from any form of rhythm monitoring) showing continuous AF: i. that are taken at least 7 days apart but less than 12 months apart. ii. If electrocardiograms are more than 12 months apart, there must be one or more SR recordings in between or within 12 months prior to consent/enrollment NOTE: The most recent ECG must be within 180 days of consent/enrollment. Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of AF from another ECG device. 3. Subject must have failed, intolerance, or contraindication to a Class I-IV AAD medication. 4. Able and willing to comply with all pre-, post-, and follow-up testing and requirements Exclusion Criteria: 1. Previously diagnosed continuous AF >12 months (longstanding persistent AF) 2. Previous left atrial surgical or catheter ablation for atrial fibrillation or a previous procedure that required an incision in the left atrium with resulting scar 3. Documented or known intracardiac thrombus on imaging 4. History of atriotomy or ventriculotomy within 4 weeks prior to the initial procedure 5. Patients with prosthetic valves 6. Diagnosed atrial myxoma 7. Acute illness or active systemic infection or sepsis 8. Patient is unlikely to survive the protocol follow up period of 36 months 9. Presence of other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results 10. Enrollment in an investigational study evaluating another device, biologic, or drug that may interfere with this clinical investigation at the time of the initial procedure or within 30 days prior to the initial procedure 11. Investigator deems at the time of screening for inclusion in the study that the patient's treatment plan does not or likely will not include use of the study catheter

Study Design


Intervention

Device:
electrophysiology study and ablation with an Abbott Ablation Catheter
During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat

Locations

Country Name City State
United States Northside Hospital Atlanta Georgia
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Brigham & Women's Hospital Boston Massachusetts
United States Erlanger Medical Center Chattanooga Tennessee
United States Doylestown Hospital Doylestown Pennsylvania
United States Heart Center Research, LLC. Huntsville Alabama
United States Arkansas Cardiology Little Rock Arkansas
United States St. Patrick Hospital Missoula Montana
United States Centennial Medical Center Nashville Tennessee
United States Ochsner Medical Center New Orleans Louisiana
United States Sentara Norfolk General Hospital Norfolk Virginia
United States Oklahoma Heart Hospital South Oklahoma City Oklahoma
United States University of Nebraska Medical Center Omaha Nebraska
United States Eisenhower Medical Center Rancho Mirage California
United States Sequoia Hospital Redwood City California
United States Chippenham Hospital Richmond Virginia
United States St. Marks Hospital Salt Lake City Utah
United States Methodist Hospital of San Antonio San Antonio Texas
United States Providence Hospital Southfield Michigan
United States North Mississippi Medical Center Tupelo Mississippi

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects with freedom from AF recurrence post 90-day blanking period at 12 months AF recurrence is defined as:
Documented AF/atrial flutter (AFL)/atrial tachycardia (AT) episodes of > 30 seconds duration following the blanking period
Repeat ablation for AF/AFL/AT following the blanking period
Cardioversion (electrical or pharmaceutical) for the treatment of AF following the blanking period
A new Class I/III AAD or a previously failed Class I/III AAD at a dose greater than the highest historical dose for AF is needed following the blanking period
12 months
Primary Rate of device and/or procedure-related serious adverse events (SAE) with onset within 7-days of the index ablation procedure Device and/or index procedure-related SAEs are defined below:
Atrio-esophageal fistula
Cardiac tamponade/perforation
Death
Heart block
Myocardial infarction (MI)
Pericarditis
Phrenic nerve injury resulting in diaphragmatic paralysis
Vagal nerve injury/gastroparesis
Pulmonary edema (respiratory insufficiency)
Pulmonary vein stenosis
Stroke/cerebrovascular accident (CVA)
Thromboembolism
Transient ischemic attack
Vascular access complications (including major bleeding events3)
7 days
Secondary the proportion of subjects with freedom from AF recurrence post 90-day blanking period at 24 months and 36 months AF recurrence is defined as:
Documented AF/atrial flutter (AFL)/atrial tachycardia (AT) episodes of > 30 seconds duration following the blanking period
Repeat ablation for AF/AFL/AT following the blanking period
Cardioversion (electrical or pharmaceutical) for the treatment of AF following the blanking period
A new Class I/III AAD or a previously failed Class I/III AAD at a dose greater than the highest historical dose for AF is needed following the blanking period
36 months
Secondary the rate of device and/or procedure-related SAEs from the index ablation procedure, descriptively evaluated at 12 months, 24 months, and 36 months Device and/or index procedure-related SAEs are defined below:
Atrioesophageal fistula
Cardiac tamponade/perforation
Death
Heart block
Myocardial infarction (MI)
Pericarditis
Phrenic nerve injury resulting in diaphragmatic paralysis
Pneumothorax
Pulmonary edema (respiratory insufficiency)
Pulmonary vein stenosis
Stroke/cerebrovascular accident (CVA)
Thromboembolism
Transient ischemic attack
Vascular access complications (including major bleeding events)
36 months
See also
  Status Clinical Trial Phase
Recruiting NCT02245009 - Safety of External Electrocardioversion in Device Patients N/A
Completed NCT02241382 - Cologne Cardioversion Study N/A
Completed NCT01439386 - Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter Phase 3
Not yet recruiting NCT06293430 - Registry on Luma Vision's VERAFEYE System (ENLIgHT)
Recruiting NCT03209583 - ATrial Tachycardia PAcing Therapy in Congenital Heart
Recruiting NCT06083012 - Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation
Recruiting NCT05883631 - RESOLVE-AF: Clinical Evaluation of the Ablacathâ„¢ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy. N/A
Recruiting NCT05014802 - Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Completed NCT05113056 - AcQForce Pulsed Field Ablation-CE N/A
Completed NCT05362656 - AutoMatic disPERsion Tagging Function Preliminary Evaluation N/A
Recruiting NCT05411614 - Hybrid AbLaTion of Atrial Fibrillation N/A
Active, not recruiting NCT05213104 - Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia Phase 3
Active, not recruiting NCT03053843 - Mediterranean Diet Plus Extravirgin Olive Oil in the Prevention of Recurrent Arrhythmias. The PREDIMAR (PREvención Con DIeta Mediterránea de Arritmias Recurrentes) Trial N/A
Completed NCT01188356 - EMERALD - AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients
Recruiting NCT03458273 - Real Zero Fluoroscopy Catheter Ablation.
Completed NCT04394923 - Relationship Between the Posterior Atrial Wall and the Esophagus: Esophageal Position and Temperature MEasurement During Atrial Fibrillation Ablation. N/A
Completed NCT02106663 - Effectiveness Study of Circumferential vs. Segmental Ablation in Paroxysmal Atrial Fibrillation N/A
Completed NCT03854149 - Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study
Recruiting NCT05488470 - QT Changes as Detected From LINQ ECG During and After Antiarrhythmic Loading (LINQ QT)
Completed NCT04579159 - The Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study (Smart in OAC - AFNET 9) N/A